- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
MannKind Corp (MNKD)
MannKind Corp stock price live, this page displays NASDAQ MNKD stock exchange data. View the MNKD premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the MannKind Corp real time stock price chart below.
What Is the MannKind Corp Stock Price Today?
The MannKind Corp stock price today is 4.060.
What Is the Stock Symbol for MannKind Corp?
The stock symbol for MannKind Corp is ""MNKD.""
What Stock Exchange Does MannKind Corp Trade On?
MannKind Corp is listed and trades on the NASDAQ stock exchange.
Is MannKind Corp a Good Stock to Buy?
Determining whether MannKind Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MNKD quote. (ISIN: US56400P7069)
What Is the MannKind Corp Stock Price Today?
The MannKind Corp stock price today is 4.060.
What Is the Stock Symbol for MannKind Corp?
The stock symbol for MannKind Corp is ""MNKD.""
What Stock Exchange Does MannKind Corp Trade On?
MannKind Corp is listed and trades on the NASDAQ stock exchange.
Is MannKind Corp a Good Stock to Buy?
Determining whether MannKind Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MNKD quote. (ISIN: US56400P7069)
4.060
-0.020(-0.49%)
Closed·
After Hours
4.120+0.060(+1.48%)
·
Fair Value
An estimate of a MannKind's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.020
4.130
52 wk Range
3.510
7.630
MNKD Scorecard
Full Analysis
High shareholder yield
Earnings results expected in 11 days
More Info
Fair Value
An estimate of a MannKind's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.0204.130
52 wk Range
3.5107.630
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MNKD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a MannKind's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
9.125
Upside
+124.75%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
- MannKind Corp stock hits 52-week low at $3.63
- Investing.com
- MannKind stock hits 52-week low at $3.70
- Investing.com
- Mannkind director Binder sells $296945 in shares
- Investing.com
- Mannkind director Binder sells $296945 in shares
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy
MannKind Corp Company Profile
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company’s product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
MannKind Corp SWOT Analysis
Inhaled Innovation | Explore MannKind's pioneering inhaled therapeutics, focusing on Tyvaso DPI and Afrezza, as the company navigates growth and challenges in specialized markets. |
Pipeline Potential | Delve into MannKind's promising pipeline, including NTM and IPF treatments, set to begin trials in June 2024, potentially reshaping the company's market position. |
Financial Trajectory | Learn about MannKind's robust 63% year-over-year revenue growth, driven by Tyvaso DPI, with 2024 revenue estimates increased to $266 million from $259.1 million. |
Market Outlook | Analyst price targets range from $5.00 to $6.50, reflecting optimism tempered by pipeline dependencies and interest expense concerns in a competitive landscape. |
MannKind Corp Earnings Call Summary for Q1/2025
- Revenue beat expectations at $78.35M, up 18% YoY, driven by 32% growth in Tyvaso DPI royalties and 18% rise in collaboration revenue
- EPS of $0.04 slightly missed forecasts, causing stock to drop 6.29% despite strong revenue performance
- Company maintains 'GREAT' financial health score of 3.56/5, with stock considered slightly undervalued by analysts
- MannKind anticipates continued growth in Tyvaso DPI royalties and potential approval of pediatric Afrezza
- CEO expressed optimism about future catalysts and company's unique inhaled therapy platform addressing unmet medical needs
Last Updated: 08/05/2025, 15:26
Read Full TranscriptCompare MNKD to Peers and Sector
Metrics to compare | MNKD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMNKDPeersSector | |
|---|---|---|---|---|
P/E Ratio | 41.0x | −4.8x | −0.5x | |
PEG Ratio | 0.18 | −0.19 | 0.00 | |
Price/Book | −21.1x | 3.0x | 2.6x | |
Price / LTM Sales | 4.1x | 11.1x | 3.2x | |
Upside (Analyst Target) | 122.8% | 110.3% | 41.7% | |
Fair Value Upside | Unlock | 15.7% | 6.1% | Unlock |
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 9.125
(+124.75% Upside)
Earnings
Latest Release
May 08, 2025
EPS / Forecast
0.07 / 0.04
Revenue / Forecast
78.35M / 75.56M
People Also Watch
FAQ
What Stock Exchange Does MannKind Trade On?
MannKind is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for MannKind?
The stock symbol for MannKind is "MNKD."
What Is the MannKind Market Cap?
As of today, MannKind market cap is 1.23B.
What Is MannKind's Earnings Per Share (TTM)?
The MannKind EPS (TTM) is 0.11.
When Is the Next MannKind Earnings Date?
MannKind will release its next earnings report on 05 Aug 2025.
From a Technical Analysis Perspective, Is MNKD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has MannKind Stock Split?
MannKind has split 1 times.
How Many Employees Does MannKind Have?
MannKind has 405 employees.
What is the current trading status of MannKind (MNKD)?
As of 26 Jul 2025, MannKind (MNKD) is trading at a price of 4.06, with a previous close of 4.08. The stock has fluctuated within a day range of 4.02 to 4.13, while its 52-week range spans from 3.51 to 7.63.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.